Revalesio’s RNS60 Enhances Synaptic Function
TACOMA, Wash., Feb. 13, 2014 /PRNewswire/ — Noted neuroscientist Dr. Rodolfo Llinas and colleagues have published an article reporting that Revalesio’s RNS60 improves synaptic transmission. Synapses connect nerve cells and allow communication through the release of neurotransmitters, which are essential for normal function of the nervous system and overall brain activity. In their work, Dr. Llinas and his coworkers used the squid giant synapse, a well-established model for researching human synapses, to investigate the impact of RNS60 on synaptic function. The paper, “Enhanced Synaptic Transmission At The Squid Giant Synapse By Artificial Seawater Based On Physically Modified Saline,” has been published in the academic journal Frontiers in Synaptic Neuroscience.
The paper demonstrates that artificial seawater made with RNS60 profoundly enhances natural synaptic function in squid neurons. Treatment with RNS60 enabled the synapse to elicit a larger postsynaptic signal compared to synapses treated with control artificial seawater and enabled a faster, more robust recovery from fatigue. Additionally, RNS60-treated synapses displayed an increase in spontaneous transmitter release and modified noise kinetics. Importantly, the functional enhancements elicited by RNS60 remained within normal physiological boundaries, indicating that RNS60 enhances synaptic transmission without negatively affecting normal function.
The importance of these findings concerns the fact that RNS60 represents a new category of therapeutics based on physical properties of solutions rather than added chemical molecules or biologics. RNS60 has previously shown to be neuro-protective and have anti-inflammatory effects in different models of neurological disorders (multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease) through direct effects on nerve cells as well as modulation of immune cell populations. The ability of RNS60 to enhance synaptic function, improve synaptic recovery and increase spontaneous transmitter release through the modulation of mitochondrial metabolism represents a new avenue for developing potential therapies for neurological disorders.
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated the ability to reduce inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases. RNS60 has completed Phase I clinical studies and is advancing into Phase II clinical development in a number of indications.
About Revalesio Corporation
Revalesio is a pioneering clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world to develop RNS60. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuroinflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com (http://www.revalesio.com).
Read more news from Revalesio Corporation.
SOURCE Revalesio Corporation